Bidzinski Mariusz

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/9463795/bidzinski-mariusz-publications-by-year.pdf

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

2,833 18 49 53 g-index h-index citations papers 3.81 3.9 55 3,393 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
49	CXCR4/ACKR3/CXCL12 axis in the lymphatic metastasis of vulvar squamous cell carcinoma. <i>Journal of Clinical Pathology</i> , 2021 ,	3.9	1
48	Contemporary principles of diagnostic and therapeutic management in cervical and ovarian neuroendocrine tumors. <i>Ginekologia Polska</i> , 2021 , 92, 312-317	1	1
47	The results of different fertility-sparing treatment modalities and obstetric outcomes in patients with early endometrial cancer and atypical endometrial hyperplasia: Case series of 30 patients and systematic review. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 263, 139	2.4 9 -147	4
46	Second-line lenvatinib in patients with recurrent endometrial cancer. <i>Gynecologic Oncology</i> , 2020 , 156, 575-582	4.9	27
45	Molecular mechanisms underlying mifepristone vagonistic action on ovarian cancer progression. <i>EBioMedicine</i> , 2019 , 47, 170-183	8.8	14
44	An evaluation of the construction of the device along with the software for digital archiving, sending the data, and supporting the diagnosis of cervical cancer. <i>Wspolczesna Onkologia</i> , 2019 , 23, 17	'4- ¹ 177	
43	Somatic mutation profiling of vulvar cancer: Exploring therapeutic targets. <i>Gynecologic Oncology</i> , 2018 , 150, 552-561	4.9	29
42	European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer. <i>International Journal of Gynecological Cancer</i> , 2017 , 27, 832-837	3.5	90
41	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1274-1284	21.7	913
40	Normalizers for microRNA quantification in plasma of patients with vulvar intraepithelial neoplasia lesions and vulvar carcinoma. <i>Tumor Biology</i> , 2017 , 39, 1010428317717140	2.9	17
39	Macrophage infiltration and genetic landscape of undifferentiated uterine sarcomas. <i>JCI Insight</i> , 2017 , 2,	9.9	12
38	Clinical significance of pretreatment serum levels of VEGF and its receptors, IL- 8, and their prognostic value in type I and II endometrial cancer patients. <i>PLoS ONE</i> , 2017 , 12, e0184576	3.7	14
37	Recommendations of the Polish Gynecological Oncology Society for the diagnosis and treatment of ovarian cancer. <i>Current Gynecologic Oncology</i> , 2017 , 15, 5-23	2	7
36	Recommendations of the Polish Gynecological Oncology Society for the diagnosis andtreatment of endometrial cancer. <i>Current Gynecologic Oncology</i> , 2017 , 15, 34-44	2	5
35	The assessment of overall survival (OS) after adjuvant chemotherapy for patients with malignant endometrial cancer in Poland. <i>Ginekologia Polska</i> , 2017 , 88, 296-301	1	1
34	Results of optimal debulking surgery with bowel resection in patients with advanced ovarian cancer. World Journal of Surgical Oncology, 2016, 14, 58	3.4	14
33	Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 78-89	21.7	162

(2010-2016)

32	The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease. <i>Tumor Biology</i> , 2016 , 37, 1271-8	2.9	29
31	Laparoscopic sentinel lymph node mapping after cervical injection of indocyanine green for endometrial cancer - preliminary report. <i>Wideochirurgia I Inne Techniki Maloinwazyjne</i> , 2015 , 10, 406-12	1.4	6
30	Uterine tumors resembling ovarian sex cord tumors, a clinicopathologic study of six cases. <i>Annals of Diagnostic Pathology</i> , 2014 , 18, 329-32	2.2	14
29	microRNAs in uterine sarcomas and mixed epithelial-mesenchymal uterine tumors: a preliminary report. <i>Tumor Biology</i> , 2013 , 34, 2153-60	2.9	26
28	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013 , 45, 371-84, 384e1-2	36.3	422
27	Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICOthe MIMOSA study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1554-61	2.2	102
26	Contraception for cancer survivors. <i>Ginekologia Polska</i> , 2013 , 84, 955-8	1	1
25	Lack of microsatellite instability in squamous cell vulvar carcinoma. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , 2012 , 91, 391-4	3.8	6
24	Identification of suitable reference genes for gene expression measurement in uterine sarcoma and carcinosarcoma tumors. <i>Clinical Biochemistry</i> , 2012 , 45, 368-71	3.5	10
23	The quality of life of women treated for cervical cancer. <i>European Journal of Oncology Nursing</i> , 2012 , 16, 59-63	2.8	17
22	High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations. <i>Cancer Genetics</i> , 2012 , 205, 94-100	2.3	18
21	Estimation of groin recurrence risk in patients with squamous cell vulvar carcinoma by the assessment of marker gene expression in the lymph nodes. <i>BMC Cancer</i> , 2012 , 12, 223	4.8	10
20	Evaluation of selected ultrasonographic parameters and marker levels in the preoperative differentiation of borderline ovarian tumors and ovarian cancers. <i>Archives of Gynecology and Obstetrics</i> , 2012 , 286, 1513-9	2.5	8
19	The promoter methylation and expression of the O6-methylguanine-DNA methyltransferase gene in uterine sarcoma and carcinosarcoma. <i>Oncology Letters</i> , 2012 , 4, 551-555	2.6	5
18	Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3841-7	2.2	96
17	PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors. <i>Human Pathology</i> , 2011 , 42, 1710-9	3.7	43
16	Evaluation of intraoperative and postoperative complications related to lymphadenectomy in ovarian cancer patients. <i>Oncology Letters</i> , 2011 , 2, 537-541	2.6	6
15	Gene therapy of locally advanced vulvar cancer with psFLT construct. <i>Wspolczesna Onkologia</i> , 2010 , 1, 11-14	1	

14	Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3107-14	2.2	317
13	Clinical significance of serum CA-125 and soluble tumor necrosis factor receptor type I in cervical adenocarcinoma patients. <i>International Journal of Gynecological Cancer</i> , 2010 , 20, 588-92	3.5	16
12	The frequency of human papillomavirus infection in polish patients with vulvar squamous cell carcinoma. <i>International Journal of Gynecological Cancer</i> , 2010 , 20, 434-7	3.5	12
11	The accuracy of the sentinel lymph node concept in early stage squamous cell vulvar carcinoma. <i>Gynecologic Oncology</i> , 2010 , 116, 473-7	4.9	40
10	Comparison of cytogenetic changes between primary and relapsed patients with borderline tumors of the ovary. <i>Cancer Genetics and Cytogenetics</i> , 2009 , 195, 157-63		2
9	Early cervical cancer managed by laparoscopy and conventional surgery: comparison of treatment results. <i>International Journal of Gynecological Cancer</i> , 2009 , 19, 1390-5	3.5	37
8	Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. <i>Gynecologic</i>	4.9	84
7	Oncology, 2008, 109, 174-81 TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study. <i>BMC Cancer</i> , 2008, 8, 27	4.8	18
6	CHFR gene is neither mutated nor hypermethylated in ovarian cancer. <i>Cancer Detection and Prevention</i> , 2007 , 31, 257-61		4
5	Nadroparine activated fibrinolysis and improvement of glomerular filtration rate in patients with FIGO IIB-IIIB cervical cancer treated with radiochemotherapy. <i>Gynecologic Oncology</i> , 2007 , 104, 24-31	4.9	1
4	Molecular genetic defects in endometrial carcinomas: microsatellite instability, PTEN and beta-catenin (CTNNB1) genes mutations. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007 , 133, 361-71	4.9	30
3	Detection of carbonic anhydrase 9-expressing tumor cells in the lymph nodes of vulvar carcinoma patients by RT-PCR. <i>International Journal of Cancer</i> , 2005 , 116, 957-62	7.5	23
2	Increased cancer risk of heterozygotes with NBS1 germline mutations in Poland. <i>International Journal of Cancer</i> , 2004 , 111, 67-71	7·5	99
1	Laparoscopic ligature of the hypogastric artery in the case of bleeding in advanced cervical cancer. <i>Gynecologic Oncology</i> , 2002 , 84, 344-8	4.9	15